Abstract:Introduction: G protein-coupled receptor (GPR) 40 is abundantly expressed in β cells. GPR40 and GPR120 are also expressed on the intestinal L cells and activating GPR40 and GPR120 can stimulate L cells to secret glucagon like peptide (GLP)-1. GW 9508 is a small-molecule agonist of GPR40 and GPR120. It dose dependently potentiates glucose-stimulated insulin secretion. In this study, we investigated whether GW9508 can directly stimulate β-cell replication in vitro and in vivo and improve islet graft function in diabetic mice. Methods: To determine β-cell proliferation in vitro, C57BL/6 mouse islets were cultured for 4 days, with and without GW9508. BrdU was added on day 3 for overnight. Insulin and BrdU immunofluorescence staining was performed on intact islets. Insulin+ and BrdU+ β cells were accounted using confocal microscope. To determine islet graft function, 100 C57BL/6 mouse islets were transplanted under the left kidney of each streptozotocin induced-diabetic C57BL/6 mouse. Recipient mice were orally treated with vehicle for GW9508 (containing dimethyl sulfoxide) or with GW9508 at 10 mg/kg/day, starting from the day of islet transplantation. All recipient mice were also intraperitoneally treated with BrdU at 100 mg/kg/day to label the replicated cells. Islet graft function was monitored by measuring blood glucose level. At 4 weeks, left nephrectomy was performed to remove the kidney bearing islet grafts to determine β-cell replication in islet grafts. Results: Insulin+ and BrdU+ β cells in each cultured islet were 13.6±1.2 cells with 0.1 μM GW9508; 18.3±1.5 cells with 1 μM GW9508; and 27.4±2.4 cells with 10 μM GW9508 (P< 0.01, vs. 10.5±0.6 cells in each untreated islet). At 2 week after islet transplantation, normoglycemia was achieved in 50% vehicle-treated mice achieved (n=10) and 100% GW9508-treated mice achieved normoglycemia (n=10). Although all recipient mice achieved normoglycemia at 4 weeks with or without treatment, normoglycemia was achieved in significantly fewer days in GW9508-treated mice. The vehicle-treated mice achieved normoglycemia in 14.4 ±2.9 days, while GW9508-treated mice only required 6.4±2.9 days (P< 0.01). The percentage of insulin+ and BrdU+ β cells in islet grafts were significantly higher in GW9508-treated mice than in vehicle-treated mice. The mean percentage of insulin+ and BrdU+ β cells in islet grafts was 23.6±6.4% in GW9508-treated mice and 6.7±3.4% in vehicle-treated mice (P< 0.01). At 30 minutes treatment, plasma GLP-1 was 9.3±2.6 pM/L in vehicle-treated mice and 14.7±4.7 pM/L in GW9508-treated mice (P< 0.05). Conclusion: Our data demonstrated that GW9508 can stimulate β-cell replication and improve islet graft function. Targeting GPR40 and/or GPR120 is a new therapeutic approach to stimulate β-cell replication and to improve islet graft function.

A Small Molecular GPR119 Agonist Improves Human Beta Cell Function and Stimulates Human Beta Cell Regeneration in Humanized Mice.

Activation of GPR119 Stimulates Human Β-Cell Replication and Neogenesis in Humanized Mice with Functional Human Islets.

Stimulating beta cell replication and improving islet graft function by GPR119 agonists.

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Stimulating Beta Cell Replication and Improving Islet Graft Function by A Gpr40 and Gpr120 Dual Agonist

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Enhancing human islet xenotransplant survival and function in diabetic immunocompetent mice through LRH-1/NR5A2 pharmacological activation

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Comparison of Exendin-4 on Beta-Cell Replication in Mouse and Human Islet Grafts

Cyanidin-3-O-Glucoside improves the viability of human islet cells treated with amylin or A<sub>1-42</sub> <i>in vitro</i>

GABA Promotes Human Β-Cell Proliferation and Modulates Glucose Homeostasis

Combined Use of GABA and Sitagliptin Promotes Human Β-Cell Proliferation and Reduces Apoptosis

Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells

P21cip-overexpression in the Mouse Beta Cells Leads to the Improved Recovery from Streptozotocin-Induced Diabetes.

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Significant expansion of the donor pool achieved by utilizing islets of variable quality in the production of allogeneic "Neo-Islets", 3-D organoids of Mesenchymal Stromal and islet cells, a novel immune-isolating biotherapy for Type I Diabetes

Co-transplantation of human adipose-derived mesenchymal stem cells with neonatal porcine islets within a prevascularized subcutaneous space augments the xenograft function

Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system